title: Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study.
abstract: OBJECTIVE
  In experimental animals, recent results suggest that the addition of inulin-type fructans such as oligofructose (OFS) in the diet decreases triacylglycerol accumulation in the liver tissue. Therefore, we have investigated the effect of daily ingestion of OFS in seven patients with nonalcoholic steatohepatitis (NASH), confirmed by liver biopsies.
  
  
  METHODS
  They received 16 g/day OFS or maltodextrine (placebo) for 8 weeks in a randomized double-blind crossover design. Energy intake, body composition, liver steatosis and blood parameters were analysed after 4 and 8 weeks of dietary supplementation.
  
  
  RESULTS
  Compared to placebo, OFS decreased significantly serum aminotransferases, aspartate aminotransferase after 8 weeks, and insulin level after 4 weeks, but this could not be related to significant effect on plasma lipids.
  
  
  CONCLUSIONS
  This pilot study supports the putative interest of OFS in the management of liver diseases associated with abnormal lipid accumulation in humans.
authors.affiliation: Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, Université Catholique de Louvain, Brussels, Belgium.
authors.forename: C A
authors.initials: CA
authors.lastname: Daubioul
authors.forename: Y
authors.initials: Y
authors.lastname: Horsmans
authors.forename: P
authors.initials: P
authors.lastname: Lambert
authors.forename: E
authors.initials: E
authors.lastname: Danse
authors.forename: N M
authors.initials: NM
authors.lastname: Delzenne
mesh_terms: D000328:Adult; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood / Q000187:drug effects; D001706:Biopsy / Q000379:methods; D001823:Body Composition / Q000502:physiology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D002149:Energy Intake / Q000502:physiology; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism*; D006505:Hepatitis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000494:pharmacology*; D010865:Pilot Projects; D011134:Polysaccharides / Q000008:administration & dosage; D013997:Time Factors; D000637:Transaminases / Q000097:blood / Q000187:drug effects
chemical_list: D007328:Insulin; D009844:Oligosaccharides; D011134:Polysaccharides; C120489:oligofructose; C008315:maltodextrin; D000637:Transaminases; D001219:Aspartate Aminotransferases; D005947:Glucose